MedTrace Logo

Benefits of Lightweight Ambulatory Oxygen Systems for Individuals With Chronic Obstructive Pulmonary Disease

NCT00325754 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2019-11-18

Study results available
· View outcomes & findings →

Summary

Chronic Obstructive Pulmonary Disease (COPD) affects over 14 million people in the United States. It is the fourth leading cause of death and the only leading cause of death for which mortality rates are rising. Medical science has developed few effective therapies for COPD. In patients with advanced COPD and chronic hypoxemia, long-term oxygen therapy (LTOT) has been shown to be uniquely beneficial. It is the only available non-surgical therapy demonstrated to prolong survival in these patients. This study will compare the clinical and physiologic benefits of two different oxygen therapy devices among hypoxemic individuals with COPD: a lightweight ambulatory oxygen device versus the standard portable E-cylinder device.

Conditions

  • Pulmonary Disease, Chronic Obstructive

Interventions

DEVICE

E-Cylinder

Portable Oxygen Therapy Delivered Via An E-Cylinder Mounted On A Wheeled Cart

DEVICE

Lightweight Cylinder

Ambulatory Oxygen Therapy Delivered Via A Carbon-Wrapped Aluminum Cylinder

Sponsors & Collaborators

  • National Heart, Lung, and Blood Institute (NHLBI)

    collaborator NIH

  • Chronic Obstructive Pulmonary Disease Clinical Research Network

    collaborator NETWORK

  • University of Minnesota

    lead OTHER

Principal Investigators

  • Richard K. Albert · Denver City-County Health/Hospitals Department

  • William Bailey · University of Alabama at Birmingham

  • Richard Casaburi · Harbor-UCLA Research & Education Institution

  • John Connett · University of Minnesota

  • Gerard J. Criner · Temple University

  • Stephen C. Lazarus · Univeristy of California at San Francisco

  • Fernando J. Martinez · University of Michigan

  • Dennis E. Niewoehner · Minnesota Veterans Medical Research and Education Foundation

  • John J. Reilly · Brigham and Women's Hospital

  • Steven M. Scharf · University of Maryland, College Park

  • Frank Sciurba · University of Pittsburgh

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-03-31
Primary Completion
2006-06-30
Completion
2006-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00325754 on ClinicalTrials.gov